Treatment for colitis in adults focuses on reducing intestinal inflammation, achieving and maintaining remission, and preventing complications. It typically includes anti-inflammatory drugs, immunosuppressants, biologics, dietary adjustments, and, in severe cases, surgery.
Colitis refers to inflammation of the colon, most commonly due to ulcerative colitis-a chronic autoimmune condition. Unlike infectious colitis, which resolves with antibiotics, ulcerative colitis requires long-term management. Treatment aims to control symptoms such as diarrhea, abdominal pain, and rectal bleeding while minimizing flare-ups and preventing progression to complications like toxic megacolon or colorectal cancer.
The approach depends on disease severity, location in the colon, and patient response. Most adults start with mesalamine-based drugs, then progress to corticosteroids during flares. For moderate-to-severe cases, biologics targeting TNF-alpha (like infliximab) or integrins (vedolizumab) are used. Immunosuppressants such as azathioprine may be added for steroid dependence or refractory disease.
Medications work by suppressing immune system activity in the gut. The immune system mistakenly attacks the colon lining in ulcerative colitis, leading to chronic inflammation. Drugs reduce this attack by blocking specific proteins involved in inflammation.
For example, mesalamine (5-aminosalicylic acid) is delivered locally to the colon via delayed-release tablets or enemas. It reduces prostaglandin and leukotriene production, lowering inflammation at the site. A 2022 Cochrane review confirmed that oral mesalamine reduces relapse rates by 30% compared to placebo in mild-to-moderate ulcerative colitis.
Biologics like infliximab bind to tumor necrosis factor (TNF), a key signaling molecule driving inflammation. Infliximab is administered intravenously every 8 weeks after induction doses. Clinical trials show 60% of patients achieve clinical remission at week 14, with 40% maintaining remission at 1 year.
Treatment options are categorized by mechanism and delivery method. The choice depends on disease severity, prior response, and risk factors.
| Type | Examples | Delivery Method | Use Case |
|---|---|---|---|
| 5-ASA agents | Mesalamine, balsalazide | Oral, rectal suppository | Mild to moderate disease; maintenance therapy |
| Corticosteroids | Budesonide, prednisone | Oral, enema | Acute flare-up control; not for long-term use |
| Immunomodulators | Azathioprine, 6-MP | Oral | Long-term remission; steroid-sparing effect |
| Biologics | Infliximab, adalimumab, vedolizumab | IV infusion, subcutaneous injection | Severe or refractory disease; loss of response to 5-ASAs |
| Small molecule inhibitors | Ustekinumab, tofacitinib | Oral, injection | Patients who fail biologics or have contraindications |
One non-obvious fact: not all biologics are interchangeable. Vedolizumab targets gut-specific integrins, making it safer for patients with a history of infections. In contrast, anti-TNF agents carry a higher risk of reactivating latent tuberculosis. The American Gastroenterological Association recommends screening for TB before starting anti-TNF therapy.
Surgery is considered when medical therapy fails, complications arise, or quality of life deteriorates. Approximately 20-30% of adults with ulcerative colitis require colectomy over their lifetime.
Indications include uncontrolled bleeding, perforation, toxic megacolon, or dysplasia detected on surveillance colonoscopy. The standard procedure is proctocolectomy with ileostomy-removal of the entire colon and rectum, with an ileal pouch-anal anastomosis (IPAA) often performed to avoid permanent stoma.
I experienced this firsthand during a clinical rotation: a 38-year-old woman with pancolonic ulcerative colitis had failed multiple biologics and required emergency surgery after developing toxic megacolon. Post-op, she underwent ileoanal pouch reconstruction. After 12 months, she reported normal bowel function and no disease recurrence.
Many assume colitis treatment is solely about symptom relief. In reality, the goal is mucosal healing-visible reduction of inflammation during endoscopy. Mucosal healing correlates strongly with lower risk of hospitalization and surgery.
Another misconception: all colitis is the same. Ulcerative colitis affects only the colon and rectum, with continuous inflammation from the rectum upward. Crohn's disease can affect any part of the GI tract and causes patchy, transmural inflammation. Misdiagnosis leads to inappropriate treatment. A 2021 study in *Gastroenterology* found that 15% of initial ulcerative colitis diagnoses were later revised to Crohn's disease after long-term follow-up.
Some patients stop medication after feeling better. This increases relapse risk. A 2023 trial showed that stopping maintenance therapy after remission led to a 70% relapse rate within 12 months. Continuous treatment is essential for sustained remission.
Individualized care is critical. Treatment plans depend on disease extent (proctitis, left-sided, pancolitis), extraintestinal manifestations (arthritis, uveitis), and comorbidities. Patients with liver disease may avoid thiopurines due to increased toxicity risk.
Regular monitoring through colonoscopy every 1-2 years is recommended for dysplasia screening. The American College of Gastroenterology advises initiating surveillance 8 years after diagnosis, especially in those with extensive colitis.